Press "Enter" to skip to content

Pfizer Says COVID-19 Vaccine Still Possible in 2020 Despite Data Lag

Shares

Key Points

  • Pfizer executives expressed measured optimism Tuesday over the prospect of providing a coronavirus vaccine in 2020 even as they signaled key data on the vaccine would not be released before the US election.
  • Rival drugmaker Merck also is working on coronavirus vaccines, but the company is at an earlier phase compared with Pfizer. 
  • Shares of Pfizer fell 1.3 percent to $37.43, while Merck shed 1.1 percent to $77.99.
  • Visit The Financial Today’s homepage for more stories.

NEW YORK — Pfizer executives expressed measured optimism Tuesday over the prospect of providing a coronavirus vaccine in 2020 even as they signaled key data on the vaccine would not be released before the US election.

Pfizer Chief Executive Albert Bourla said the drug giant could supply some 40 million doses in the United States in 2020 if clinical testing proceeds as expected and regulators approve a vaccine.

“If all goes well, we will be ready to distribute an initial number of doses,” said Bourla, who pointed to a US government contract for Pfizer to supply 40 million doses by the end of this year and 100 million doses by March 2021.

Get unlimited access to TFT Premium content for FREE!

Join 23,000+ subscribers and enjoy free access to TFT premium news & stories!

Be First to Comment

Leave a Reply